Compare Humana Inc (HUM) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs KLA Corp. — how do they compare? Humana Inc trades at $405.62 (market cap $47.81B), while KLA Corp. trades at $216.98 (market cap $271.18B). The key difference: KLA Corp. is far larger — about 5.7× Humana Inc's market cap, and Humana Inc pays the higher dividend (0.89%). Which is the better fit depends on your goals.
| HUM | KLAC | |
|---|---|---|
Market Cap | $47.81B | $271.18B |
Sector | Health | Technology |
52-Week High | $409.42 | $301.71 |
52-Week Low | $163.67 | $84.39 |
Enterprise Value | $56.85B | $272.37B |
Dividend Yield | 0.89% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $398.09, down 0.48% with a bullish technical signal from moving averages. The company shows strong revenue growth to $129.66B in 2025 but faces margin compression with net income margin declining to 0.82%. Recent earnings have consistently beaten expectations, and analyst sentiment is mixed with 34% buy ratings but a consensus price target of $354.33 below current levels.
The outlook suggests cautious optimism with Medicare Advantage expansion opportunities but significant margin pressure and regulatory risks. Key investment considerations include the company's ability to achieve its 3% Medicare Advantage margin target by 2028 while navigating increased healthcare utilization costs and competitive pressures in the insurance sector.
KLA Corporation (KLAC) trades at $207.82, down 2.32% amid a semiconductor sector correction. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.94 versus $0.917 expected, and robust profitability with a 35.66% net margin. Technical indicators signal bearish momentum with key support at $200, while analyst consensus remains bullish with a $243.43 price target. Recent corporate actions include a 1:10 stock split effective June 12, 2026, and a $2.30 dividend paid June 2, 2026.
KLAC's outlook is supported by dominant market positioning in semiconductor process control and AI-driven demand, but high valuation multiples (P/E 60.25) and sector volatility present risks. The stock offers growth potential through semiconductor equipment expansion, though investors should monitor industry cyclicality and competitive pressures from peers like Applied Materials.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
